Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIP in PH-ILD
NCT05176951Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD) comparing Treprostinil Palmitil with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events, Serious Adverse Events and 1 more. Started Dec 2022; status: completed.
02
Drugs
treprostinil palmitil
03
Conditions
Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT05176951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176951.